Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTPO + CsA vs CsA Alone in Lower-risk MDS With Thrombocytopenia
NCT07653581Phase 3Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2026
- Primary completion
- Dec 2028
01
Overview
A Phase 3 trial of recombinant human thrombopoietin in myelodysplastic syndrome (MDS), sponsored by Peking Union Medical College Hospital. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
recombinant human thrombopoietin
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07653581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07653581.